drugset / Trial / NCT05787561
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Phase 2
Active not recruiting
40 enrolled
Memorial Sloan Kettering Cancer Center
Verastem, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Timeline
- Start
- 2023-03-15
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 3.2 mg | Oral |
| Subject | Defactinib | Small molecule | 200 mg | Oral |